Health notices · Sunday 13 September

Recall class II for certain levothyroxine 300 mcg tablets

FDA · Recall

If you take levothyroxine sodium tablets (300 mcg/0.3 mg) in 90-count bottles, this FDA notice says the drug may be subpotent, meaning it may contain less active medicine than it should.

The notice is for tablets manufactured for Accord Healthcare, Inc. and manufactured by Intas Pharmaceuticals Limited; it was distributed nationwide in the United States.

Because levothyroxine is used to treat thyroid conditions, having a weaker tablet than expected could affect how your thyroid medicine works for you tomorrow.

Read the original notice

FDA approval for Binosto (alendronate sodium) for osteoporosis

FDA · Approval

If you have osteoporosis, the US Food and Drug Administration has approved Binosto (alendronate sodium). Binosto is a bisphosphonate, which is a medicine used to help strengthen bones.

Binosto is indicated for treatment of osteoporosis in postmenopausal women and to increase bone mass in men with osteoporosis.

Your care may include reassessing how long to use it. The label says the optimal duration has not been determined, and people at low risk for fracture should be considered for stopping after 3 to 5 years.

If you stop, the label says your risk for fracture should be re-evaluated periodically.

Read the original notice

CDC shares fall prevention resources for older adults

Centers for Disease Control and Prevention (CDC) · Guidance

If you are an older adult, or you care for one, CDC’s STEADI resources offer educational materials to help prevent falls and lower fall risks.

The page includes brochures and checklists on topics like footwear, home safety, medication risk, and postural hypotension (low blood pressure when standing).

CDC also provides graphics you can use to “stay STEADI” and a “MyMobility Plan” to help you stay safe, mobile, and independent.

Read the original notice